Tandem Diabetes Care Stock Alpha and Beta Analysis
| TNDM Stock | USD 19.17 0.99 5.45% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tandem Diabetes Care. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tandem Diabetes over a specified time horizon. Remember, high Tandem Diabetes' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tandem Diabetes' market risk premium analysis include:
Beta 0.82 | Alpha (0.50) | Risk 5.35 | Sharpe Ratio (0.14) | Expected Return (0.76) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Tandem |
Tandem Diabetes Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tandem Diabetes market risk premium is the additional return an investor will receive from holding Tandem Diabetes long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tandem Diabetes. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tandem Diabetes' performance over market.| α | -0.5 | β | 0.82 |
Tandem Diabetes expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tandem Diabetes' Buy-and-hold return. Our buy-and-hold chart shows how Tandem Diabetes performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Tandem Diabetes Market Price Analysis
Market price analysis indicators help investors to evaluate how Tandem Diabetes stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tandem Diabetes shares will generate the highest return on investment. By understating and applying Tandem Diabetes stock market price indicators, traders can identify Tandem Diabetes position entry and exit signals to maximize returns.
Tandem Diabetes Return and Market Media
The median price of Tandem Diabetes for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 35.0 with a coefficient of variation of 19.04. The daily time series for the period is distributed with a sample standard deviation of 6.16, arithmetic mean of 32.35, and mean deviation of 4.54. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings | 02/13/2025 |
2 | Disposition of 595 shares by Rick Carpenter of Tandem Diabetes subject to Rule 16b-3 | 02/18/2025 |
3 | Acquisition by Shannon Hansen of 531 shares of Tandem Diabetes subject to Rule 16b-3 | 02/21/2025 |
4 | Tandem Raises USD 10M in its Pre-seed Round to Revolutionize Pet Healthcare | 02/24/2025 |
5 | Risen Achieves 30.99 percent Efficiency with HJT-Perovskite Tandem Solar Cells | 02/26/2025 |
6 | Q4 2024 Tandem Diabetes Care Inc Earnings Call Transcript | 02/27/2025 |
7 | Not Many Are Piling Into Tandem Diabetes Care, Inc. Stock Yet As It Plummets 40 | 02/28/2025 |
8 | Tandem Diabetes Care Inc Stock Price Down 2.44 percent on Mar 3 | 03/03/2025 |
9 | Advisor360 Introduces Tandem A CRM for Independent Financial Advisors | 03/04/2025 |
10 | Tandem Diabetes Care downgraded to Equal-weight on guidance concerns | 03/05/2025 |
11 | Acquisition by Kyrillos Jean-claude of 10538 shares of Tandem Diabetes at 18.1217 subject to Rule 16b-3 | 03/07/2025 |
12 | Victory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. - Defense World | 03/12/2025 |
About Tandem Diabetes Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tandem or other stocks. Alpha measures the amount that position in Tandem Diabetes Care has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 6.97 | 7.66 | 10.07 | 8.12 | Days Of Inventory On Hand | 104.47 | 151.69 | 121.18 | 173.07 |
Tandem Diabetes Upcoming Company Events
As portrayed in its financial statements, the presentation of Tandem Diabetes' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tandem Diabetes' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tandem Diabetes' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tandem Diabetes. Please utilize our Beneish M Score to check the likelihood of Tandem Diabetes' management manipulating its earnings.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Tandem Diabetes
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Tandem Diabetes Backtesting, Tandem Diabetes Valuation, Tandem Diabetes Correlation, Tandem Diabetes Hype Analysis, Tandem Diabetes Volatility, Tandem Diabetes History and analyze Tandem Diabetes Performance. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Tandem Diabetes technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.